Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF
NCT: NCT07593638 · NOT_YET_RECRUITING
Brief Summary
Clinical trial The goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are: * Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant * What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery Participants will: * Be submitted to DPMAS plus half dose plasma exchange daily according to protocol. * Monitoring will be continuous in the ICU
Frequently Asked Questions
What is Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF?
Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF is a clinical trial registered under NCT07593638. Current status: NOT_YET_RECRUITING.
What is the status of NCT07593638?
The current status of NCT07593638 (Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF) is: NOT_YET_RECRUITING.
When did Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF start?
Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF started on 2026-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.